Anaesthetic formulation

ABSTRACT

The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.

FILING DATA

This application is associated with and claims priority from U.S.Provisional Patent Application No. 61/297,249, filed on 21 Jan. 2010,entitled “Anaesthetic formulation” AND. U.S. Provisional PatentApplication No. 61/385,318 filed on 22 Sep. 2010, entitled “Anaestheticformulation”, the entire contents of which, are incorporated herein byreference.

FIELD

The present invention relates generally to the field of drug deliverysystems for neuroactive steroid anaesthetic agents. More particularly,anaesthetic and sedative compositions are provided in the form ofhost/guest preparations comprising one or more neuroactive steroidanaesthetics and a cyclodextrin or a modified form thereof.

BACKGROUND

Bibliographic details of references provided in the subjectspecification are listed at the end of the specification.

Reference to any prior art is not, and should not be taken as anacknowledgment or any form of suggestion that this prior art forms partof the common general knowledge in any country.

Drug delivery systems aim to provide the required amount of drugsystemically or to a targeted site for a time and under conditionssufficient to have the desired effect. Some drug delivery systemsrequire carrier materials to mitigate particular undesirable propertiesof the drugs. One such type of carrier molecule is a cyclodextrin whichacts as a host for a selected guest molecule.

Cyclodextrins are cyclic oligosaccharides with hydroxyl groups on theirouter surface and a void central cavity which has a lipophiliccharacter. Cyclodextrins are capable of forming inclusion complexes withhydrophobic molecules. The stability of the resulting host/guest complexdepends on how readily the guest molecule occupies the central cavity ofthe host.

The most common cyclodextrins are α-, β- and γ-cyclodextrins consistingof 6, 7 and 8α-1,4-linked glucose units, respectively. Cyclodextrinshave relatively low solubility in water and organic solvents and thislimits their use in pharmaceutical formulations. For a description ofthe general chemistry of cyclodextrin, reference can be made to Frommingand Szejtlic (eds), Cyclodextrins in Pharmacy, Kluwer: Dordrecht, TheNetherlands, 1994: Atwood, Davies, MacNicol and Vogtie (Eds),Comprehensive Supramolecular Chemistry Vol 4, Pergamon: Oxford UK, 1996;and Thomason, Crit. Rev Ther Drug Carrier Syst 14:1, 1997.

Alphaxalone [Alfaxalone or 3-α-hydroxy-5-α-,pregnan-11,20-dione] is apotent neuroactive steroid anaesthetic currently used in veterinarymedicine (Child et al., British Journal of Anaesthesia 43:2-13, 1971).

Alphaxalone was widely used around the world as an intravenousanaesthetic together with alphadolone [Althesin; Alfathesin] in humanpatients until 1983. Although these anaesthetics have a high therapeuticindex, they were nevertheless withdrawn from clinical practice due tooccasional, unpredictable yet severe anaphylactoid reactions to apolyethoxylated castor oil excipient (Cremophor EL [RegisteredTrademark]).

Currently, a lipid formulation of di-isopropyl phenol (propofol) is themost highly used anaesthetic agent. Propofol, however, can becontraindicated in certain at risk patients due to its lowering effecton blood pressure, the effect it has on reducing cardiac output and itcan adversely affect respiratory control. In particular, propofol isformulated in a lipid emulsion which can support microbial growth ifcontaminated. The formulation cannot, in fact, be sterilized. There havebeen instances where microbially contaminated propofol formulations haveresulted in patients becoming infected. One other issue with the currentpropofol formulation is the pain induced following or during intravenousinjection. Attempts to re-formulate in a water-based preparation haveled to increased injection pain. Propofol also can lead tocardiovascular and respiratory depression and has a low therapeuticindex of 5, i.e. only 5 times the normal anaesthetic dose can lead todeath. Furthermore, the anaesthetic is incompatible with plastic storagecontainers and plastic syringes which complicates syringe deliveryequipment which is frequently in standard use for intravenousanaesthesia and sedation. The drug can also cause hyperlipidaemia andcan induce toxicity when used in a larger dose by infusion. This isparticularly problematic in the intensive care setting.

A neuroactive steroid anaesthetic has the potential for being moreefficacious with fewer side effects than propofol.

There is a need, therefore, to develop a suitable formulation to enablethe use of a neuroactive steroid anaesthetic agent in subjects.

SUMMARY

Throughout this specification, unless the context requires otherwise,the word “comprise”, or variations such as “comprises” or “comprising”,will be understood to imply the inclusion of a stated element or integeror method step or group of elements or integers or method steps but notthe exclusion of any other element or integer or method step or group ofelements or integers or method steps.

The present invention provides a host/guest complex formulationcomprising a neuroactive steroid anaesthetic and a cyclodextrin ormodified form thereof for use in inducing anaesthesia or sedation inmammalian subjects. Generally, the neuroactive steroid anaesthetic issparingly soluble. The host/guest complex formulation is, therefore, adrug delivery system for a neuroactive steroid anaesthetic. In anembodiment, the cyclodextrin is a modified polyanionic β-cyclodextrinand the neuroactive steroid anaesthetic is selected from alphaxalone,alphadolone, acebrochol, allopregnanolone, eltanolone (pregnanolone),ganaxolone, hydroxydione, minaxolone, Org20599, Org21465 andtetrahydrodeoxycorticosterone and a pharmacologically acceptablederivative, salt or pro-drug form thereof. However, all cyclodextrinsare contemplated herein including γ and α cyclodextrins or theirmodified forms as well as their salts. The term “derivative” includesdeuterated derivatives of the neuroactive steroid anaesthetic.Deuterated derivatives are contemplated for use as improved medicaments.One or more hydrogen atoms may be replaced by deuterium. Modified formsof cyclodextrins include methylated, hydroxyalkylated, branched,alkylated, acylated and anionic cyclodextrins. By “alkylated” includesan alkyl ether derivative as well as an alkyl ether-alkyl ethercyclodextrin. The agent “alphadolone” includes its salt, alphadoloneacetate. Reference to a cyclodextrin or a modified form thereof includesits salts (e.g. a sodium salt).

Accordingly, one aspect of the present invention is directed to ananaesthetic or sedative composition comprising a neuroactive steroidanaesthetic formulated with a cyclodextrin or modified form thereof.

The anaesthetic or sedative formulation of the present inventionexhibits features such as being sterilizable, causes reduced incidenceof pain on injection, has a larger therapeutic index relative topropofol (including a therapeutic index greater than 5), is capable ofstorage in a plastic container and induces a rapid induction ofanaesthesia to surgical levels with similar or more rapid awakening timethan propofol or Althesin (alphaxalone and alphadolone).

Hence, another aspect of the present invention provides an anaestheticor sedative composition comprising a neuroactive steroid anaesthetic anda cyclodextrin or modified form thereof wherein the anaesthetic andcyclodextrin are formulated to provide an anaesthetic composition whichexhibits a property selected from being sterilizable, exhibiting minimalpain on intravenous injection, having a therapeutic index greater than 5and is storable in a plastic container. In an embodiment, theformulation has one, two, three or all four of these properties.

In a related embodiment, the present invention provides an anaestheticor sedative delivery host/guest composition comprising a cyclodextrinhost or a modified form thereof with a neuroactive steroid anaestheticdrug guest, the host/guest composition formulated to be sterilizable,administrable by intravenous injection with minimal pain and to exhibita therapeutic index of greater than 5. The formulation may also bestorable in a plastic container.

More particularly, the present invention provides an anaesthetic orsedative composition comprising a neuroactive steroid anaestheticselected from alphaxalone, alphadolone, acebrochol, allopregnanolone,eltanolone (pregnanolone), ganaxolone, hydroxydione, minaxolone,Org20599, Org21465 and tetrahydrodeoxycorticosterone andpharmacologically acceptable derivatives, salts and pro-drug formsthereof formulated with a cyclodextrin or modified form thereof.

Even more particularly, the present invention is directed to ananaesthetic or sedative composition comprising a neuroactive steroidanaesthetic selected from alphaxalone, alphadolone, acebrochol,allopregnanolone, eltanolone (pregnanolone), ganaxolone, hydroxydione,minaxolone, Org20599, Org21465 and tetrahydrodeoxycorticosterone andpharmacologically acceptable derivatives, salts and pro-drug formsthereof formulated with a cyclodextrin or a modified form thereofwherein the composition exhibits a property selected from beingsterilizable, exhibiting minimal pain on intravenous injection, having atherapeutic index greater than 5 and is storable in a plastic container.

A particular cyclodextrin useful in the practice of the presentinvention is a sulfoalkyl ether cyclodextrin such as (7) sulfobutylether β-cyclodextrin. This compound can be prepared as described in U.S.Pat. No. 5,376,645. Another, useful cyclodextrin is an alkyl etherderivative including a sulfoalkyl ether-alkyl ether cyclodextrin.However, the present invention extends to other cyclodextrin derivativessuch as methylated, hydroxyalkylated, branched, acylated and anionicforms. The anaesthetic formulation of the present invention enablesinjectable administration to mammalian subjects and in particular humanpatients.

Another aspect of the present invention provides an anaesthetic orsedative composition comprising a neuroactive steroid selected fromalphaxalone, alphadolone, acebrochol, allopregnanolone, eltanolone(pregnanolone), ganaxolone, hydroxydione, minaxolone, Org20599, Org21465and tetrahydrodeoxycorticosterone and a pharmacologically acceptablederivative, salt or pro-drug form thereof formulated with a sulfoalkylether cyclodextrin or modified form thereof to generate a sterilizablecomposition with a therapeutic index of greater than 5.

In an embodiment, the composition is also storable in a plasticcontainer.

The formulation may comprise a buffer to maintain pH within a range offrom about pH5.5 to pH8. Alternatively, the formulation may not bebuffered wherein the pH of the formulation may be from about pH3 toabout pH9.5. The formulation may also comprise a preservative,anti-microbial agent and/or an agent which reduces toxicity. Inaddition, to improve solubility and/or stability, a co-polymer may beincluded. Examples of suitable co-polymers include hydroxylpropyl methylcellulose (HPMC), polyvinyl pyrollidone (PVP), and carboxymethylcellulose (CMC).

The present invention further contemplates inducing or maintaining byinfusion or intermittent bolus administration, anaesthesia or sedationin a subject, the method comprising administering ananaesthetic-effective amount of a neuroactive steroid anaestheticformulated with a cyclodextrin, for a time and under conditions toinduce anaesthesia or sedation.

More particularly, the present invention provides a method of inducingor maintaining by infusion, or intermittent bolus administration,anaesthesia or sedation in a subject, the method comprisingadministering an anaesthetic-effective amount of a neuroactive steroidanaesthetic selected from alphaxalone, alphadolone, acebrochol,allopregnanolone, eltanolone (pregnanolone), ganaxolone, hydroxydione,minaxolone, Org20599, Org21465 and tetrahydrodeoxycorticosterone andpharmacologically acceptable derivatives, salts or pro-drug formsthereof formulated with a cyclodextrin or modified form thereof for atime and under conditions sufficient to induce anaesthesia or sedationwherein the anaesthetic or sedative formulation exhibits a propertyselected from being sterilizable, exhibiting minimal pain on intravenousinjection and having a therapeutic index greater than 5.

In an embodiment, the formulation is also storable in a plasticcontainer.

Generally, the molar ratio of neuroactive steroid anaesthetic tocyclodextrin is from about 1:1 to about 1:6, more particularly about 1:1to about 1:4, even more particularly about 1:1 to 1:3 and still moreparticularly about 1:2.

These aspects of the present invention extend to inducing or maintainingby infusion or intermittent bolus administration, anaesthesia orsedation or both in subjects.

The formulation may be packaged for sale with a set of instructions. Theinstructions may include a patient management protocol comprisingadministering to the patient an effective amount of neuroactive steroidanaesthetic such as selected from alphaxalone, alphadolone, acebrochol,allopregnanolone, eltanolone (pregnanolone), ganaxolone, hydroxydione,minaxolone, Org20599, Org21465 and tetrahydrodeoxycorticosterone andpharmacologically acceptable derivatives, salts and pro-drug formsthereof formulated with a cyclodextrin for a time and under conditionssufficient to induce anaesthesia. As indicated above, a suitablecyclodextrin includes a sulfoalkyl ether dextrin, such as (7) sulfobutylether β-cyclodextrin as well as alkyl ether derivatives such assulfoalkyl-alkyl ether cyclodextrins. Other derivatives includemethylated, hydroxyalkylated, branched, alkylated, acylated and anioniccyclodextrins.

The present invention further contemplates the use of a neuroactivesteroid anaesthetic and a cyclodextrin or modified form thereof, in themanufacture of a medicament to induce anaesthesia in a subject. In aparticular embodiment, the neuroactive steroid anaesthetic is selectedfrom alphaxalone, alphadolone, acebrochol, allopregnanolone, eltanolone(pregnanolone), ganaxolone, hydroxydione, minaxolone, Org20599, Org21465and tetrahydrodeoxycorticosterone and pharmacologically acceptablederivatives, salts and pro-drug forms thereof.

Kits comprising in compartmental form a neuroactive steroid anaestheticin a first compartment and a cyclodextrin, such as a sulfoalkyl ethercyclodextrin, in a second compartment and optionally excipients and/orco-polymers in a third or other compartment are also contemplatedherein. The kit may be in the form of a modified syringe.

Labeled forms of the neuroactive steroid anaesthetic are also useful inmonitoring and tracking the anaesthetic during sedation or anaesthesia.Kits and apparatus are therefore provided herein to assist in themonitoring of labelled neuroactive steroid anaesthetics. Labeledderivatives include deuterated, tritiated and other labeled agents.

BRIEF DESCRIPTION OF THE FIGURES

Some figures contain color representations or entities. Colorphotographs are available from the Patentee upon request or from anappropriate Patent Office. A fee may be imposed if obtained from aPatent Office.

FIG. 1 a through 1 f are graphical representations of experiments onmale Wistar rats implanted with indwelling internal jugular veinintravenous catheters under halothane anaesthesia and then provided withpropofol (a,b), Althesin [alphaxalone and alphadolonc acetate] (c,d) orPhaxan_(CD) [alphaxalone in a 1:2 molar complexation ratio with (7)sulfobutyl ether β-cyclodextrin] (e,f).

FIG. 2 is a graphical representation of lethal dosing of two alphaxalonepreparations [Phaxan_(CD) and Althesin in rats].

FIG. 3 is a graphical representation of a probit plot for lethalitydosing of an Althesin preparation in rats.

FIG. 4 is a graphical representation of sleep time in rats usingrepeated doses of Phaxan_(CD) (alphaxalone in a 1:2 molar complexationratio with (7) sulfobutyl ether β-cyclodextrin).

FIG. 5 is a graphical representation of righting reflex time responsecurves in rats using pregnanolone in a (7) sulfobutyl etherβ-cyclodextrin.

FIG. 6 is a graphical representation of tail pinch time response curvein rats using pregnanolone in a (7) sulfobutyl ether β-cyclodextrin.

FIG. 7 is a graphical representation of rotarod test time response curvein rats using pregnanolone in a (7) sulfobutyl ether β-cyclodextrin.

FIG. 8 is a graphical representation of righting reflex time responsecurves in rats using alphadolone in a (7) sulfobutyl etherβ-cyclodextrin.

FIG. 9 is a graphical representation of tail pinch time response curvesin rats using alphadolone in a (7) sulfobutyl ether β-cyclodextrin.

FIG. 10 is a graphical representation of rotarod test time responsecurves in rats using alphadolone in a (7) sulfobutyl etherβ-cyclodextrin.

FIG. 11 is a graphical representation of percentage change in meansystolic blood pressure in rats after injection with propofol, Althesinor Phaxan_(CD).

FIG. 12 is a graphical representation of percentage change in meandiastolic blood pressure in rats after injection with propofol, Althesinor Phaxan_(CD).

Reference to “Phaxan_(CD)” means an alphaxalone preparation with (7)sulfobutyl ether β-cyclodextrin.

DETAILED DESCRIPTION

The present invention provides a drug delivery system for a neuroactivesteroid anaesthetic. Generally, the neuroactive steroid anaesthetic issparingly soluble in water. The drug delivery system comprises a hostcarrier in the form of a cyclodextrin or modified form thereof.Reference to “cyclodextrin” includes in one embodiment an α-, β- orγ-cyclodextrin or a modified or derivatized form thereof. Reference to“cyclodextrin” in another embodiment includes a sulfoalkyl ether dextrinsuch as (7) sulfobutyl ether β-cyclodextrin or an alkyl ether derivativethereof such as a sulfobutyl ether-alkyl ether cyclodextrin. Derivativesof cyclodextrins include methylated, hydroxyalkylated, branched,alkylated, acylated and anionic cyclodextrins. By “alkylated” includesan alkyl ether derivative such as an alkyl ether-alkyl ethercyclodextrin. Particular cyclodextrins contemplated herein are shown inTable 7 [Uekama et al., Chem. Rev. 98: 2045-2076, 1998] and includeβ-cyclodextrin sulfobutyl ethers, ethyl ethers, β-cyclodextrinsulfobutyl ethers (flat), γ-cyclodextrin sulfobutyl ethers andα-cyclodextrin sulfobutyl ethers and their salts (e.g. sodium salts).

The drug delivery system of the present invention enables a neuroactivesteroid anaesthetic to be administered to a subject in a sterilizedform. Furthermore, the delivery itself is with less pain compared to theintravenous administration of propofol. The formulation of the presentinvention additionally has a therapeutic index greater than 5 (meaningthat administration of greater than 5 times the anaesthetic dose canlead to death in a test animal). By “greater than 5” means a therapeuticindex of between 5 and 200 including 10, 20, 30, 40, 50, 60, 70, 80, 90,100, 110, 120, 130, 140, 150, 160, 170, 180, 190 and 200 as well asintegers or fractions in between. The formulation of the presentinvention is also storable in a plastic container and is compatible foruse in plastic delivery apparatus.

Accordingly, an aspect of the present invention provides an anaestheticor sedative delivery host/guest composition comprising a cyclodextrinhost or modified form thereof with a neuroactive steroid anaestheticdrug guest, the host/guest composition formulated to be sterilizable,administrable by intravenous injection with minimal pain and to exhibita therapeutic index of greater than 5. In an embodiment, the formulationmay also be storable in a plastic container. The formulation may exhibitone, two, three or all four of these properties.

By “reduced pain” means compared to a formulation comprising propofol asa reference.

The formulation is useful for inducing anaesthesia or sedation inmammalian subjects and in particular human subjects.

In an embodiment, the neuroactive steroid is selected from alphaxalone,alphadolone, acebrochol, allopregnanolone, eltanolone (pregnanolone),ganaxolone, hydroxydione, minaxolone, Org 20599, Org 21465 andtetrahydrodeoxycorticosterone and a pharmacologically acceptablederivative, salt or pro-drug form thereof.

An example of a pharmacologically acceptable salt is alphadoloneacetate, which is encompassed by the present invention. An example of aderivative of a neuroactive steroid anaesthetic is a deuteratedderivative. A “modified” cyclodextrin includes a derivative of acyclodextrin.

Accordingly, another aspect of the present invention is directed to adrug delivery host/guest composition comprising a cyclodextrin host ormodified form thereof with a neuroactive steroid anaesthetic drug guestselected from alphaxalone, alphadolone, acebrochol, allopregnanolone,eltanolone (pregnanolone), ganaxolone, hydroxydionc, minaxolone, Org20599, Org 21465 and tetrahydrodeoxycorticosterone and apharmacologically acceptable derivative, salt or pro-drug form thereof,the host/guest composition being sterilizable, administrable byintravenous injection with minimal pain, exhibiting a therapeutic indexof greater than 5 and/or storable in a plastic container. Theformulation can also initiate rapid induction of anaesthesia to surgicallevels with similar or more rapid wakening time compared to propofol. Asindicated above, the formulation may exhibit one, two, three or all ofthese properties.

The composition of the present invention may be referred to as aformulation, host/guest composition, drug delivery system, medicament,anaesthetic or sedative as well as more descriptively such as ananaesthetic formulation or sedative formulation.

Another aspect of the present invention provides an anaesthetic orsedative formulation comprising a neuroactive steroid anaesthetic and acyclodextrin or modified form thereof, the formulation exhibitingproperties including being sterilizable, inducing reduced pain onintravenous administration, having a therapeutic index of greater than 5and/or being storable in a plastic container.

More particularly, the present invention relates to an anaesthetic orsedative formulation comprising a neuroactive steroid anaestheticselected from alphaxalone, alphadolonc, acebrochol, allopregnanolone,eltanolone (pregnanolone), ganaxolone, hydroxydione, minaxolone, Org20599, Org 21465 and tetrahydrodeoxycorticosterone and apharmacologically acceptable derivative, salt or pro-drug form thereof,the formulation exhibiting properties including being sterilizable,inducing reduced pain on intravenous administration and having atherapeutic index of greater than 5.

In an embodiment, the formulation is also storable in a plasticcontainer.

The present invention extends to mixtures of two or more neuroactivesteroid anaesthetic drugs such as a composition comprising alphaxaloneand alphadolone and/or alphadolone acetate or their pharmacologicallyacceptable derivatives, salts or pro-drug forms.

A “pharmacologically acceptable derivative” is a derivative that stillinduces anaesthesia whilst not increasing adverse side effects. The term“derivative” includes deuterated derivatives where one or more hydrogenatoms are replaced with deuterium. This can lead to improved efficacy.Furthermore, the anaesthetic agents may be subject to alkylation,alkoxylation, acetylation and/or phosphorylation to generate otherderivatives. Other types of derivatives include deuterated or tritiatedor other labeled forms useful for monitoring and tracking theanaesthetic in the body. The terms “derivative” and “modified form” areused interchangeably herein. Salts of alphadolone include alphadoloneacetate. Reference to pro-drugs include transported pro-drugs.

In an embodiment, the cyclodextrin is a β-cyclodextrin or a modifiedform thereof such as but not limited to a sulfoalkyl ether dextrin. Aparticularly useful sulfoalkyl ether dextrin is (7) sulfobutyl etherβ-cyclodextrin. Alkyl ether derivatives are also contemplated such as asulfoalkyl ether-alkyl ether cyclodextrin. An example of an alkyl etherderivative is a sulfobutyl ether-alkyl ether cyclodextrin. Othercyclodextrins contemplated herein are listed in Table 7 and includemethylated, hydroxyalkylated, alkylated, branched, acylated and anionicderivatives.

Accordingly, an aspect of the present invention provides an anaestheticor sedative delivery host/guest composition comprising a sulfoalkylether dextrin host or modified form thereof with a neuroactive steroidanaesthetic drug guest, the host/guest composition formulated to besterilizable, administrable by intravenous injection with minimal pain,exhibiting a therapeutic index of greater than 5. In an embodiment, theformulation may also be storable in a plastic container.

Another aspect of the present invention is directed to a drug deliveryhost/guest composition comprising a sulfoalkyl ether dextrin host ormodified form thereof with a neuroactive steroid anaesthetic drug guestselected from alphaxalone, alphadolone, acebrochol, allopregnanolone,eltanolone (pregnanolone), ganaxolone, hydroxydione, minaxolone, Org20599, Org 21465 and tetrahydrodeoxycorticosterone and apharmacologically acceptable derivative, salt or pro-drug form thereof,the host/guest composition to be sterilizable, administrable, byintravenous injection with minimal pain and exhibiting a therapeuticindex of greater than 5.

In an embodiment, the composition is also storable in a plasticcontainer.

Another aspect of the present invention provides an anaesthetic orsedative formulation comprising a neuroactive steroid anaesthetic and asulfoalkyl ether dextrin or modified form thereof, the formulationexhibiting properties including being sterilizable, inducing reducedpain on intravenous administration, having a therapeutic index ofgreater than 5 and/or being storable in a plastic container.

As indicated above one particularly useful sulfoalkyl ether dextrin is(7) sulfobutyl ether β-cyclodextrin. Of the properties exhibited, in aparticular embodiment, the formulation exhibits two or more, three ormore or all properties. These properties include imitating rapidinduction of anaesthesia to surgical levels with similar or more rapidwakening time such as compared to propofol.

The formulation between the neuroactive steroid and cyclodextrin isgenerally in a molar ratio of from 1:1 to 1:6 (neuroactivesteroid:cyclodextrin), more particularly about 1:1 to 1:4, even moreparticularly about 1:1 to 1:3 and still more particularly about 1:2. Therange 1:1 to 1:6 includes 1:1, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6,1:1.7, 1:1.8, 1:1.9, 1:2, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5, 1:2.6,1:2.7, 1:2.8, 1:2.9, 1:3, 1:3.1, 1:3.2, 1:3.3, 1:3.4, 1:3.5, 1:3.6,1:3.7, 1:3.8, 1:3.9, 1:4, 1:4.1, 1:4.2, 1:4.3; 1:4.4, 1:4.5, 1:4.6,1:4.7, 1:4.8, 1:4.9, 1:5, 1:5.1, 1:5.2, 1:5.3, 1:5.4, 1:5.5, 1:5.6,1:5.7, 1:5.8, 1:5.9 and 1:6.

Accordingly, the present invention provides a drug delivery host/guestcomposition comprising a cyclodextrin host or modified form thereof witha neuroactive steroid drug guest, wherein the molar ratio of neuroactivesteroid to cyclodextrin is from about 1:1 to about 1:6 and wherein thecomposition is formulated to be sterilizable, administrable, byintravenous injection with minimal pain and exhibiting a therapeuticindex of greater than 5. In an embodiment, the formulation may also bestorable in a plastic container.

More particularly, the present invention is directed to a drug deliveryhost/guest composition comprising a cyclodextrin selected from an α-, β-or γ-cyclodextrin or a modified form thereof including a sulfoalkylether dextrin or sulfoalkyl ether-alkyl ether derivative or otherderivatives listed in Table 7 and a neuroactive steroid drug guestselected from alphaxalone, alphadolone, acebrochol, allopregnanolone,eltanolone (pregnanolone), ganaxolone, hydroxydione, minaxolone, Org20599, Org 21465 and tetrahydrodeoxycorticosterone and apharmacologically acceptable derivative, salt or pro-drug form thereof,wherein the molar ratio of a neuroactive steroid to cyclodextrin is fromabout 1:1 to about 1:6 and wherein the composition is formulated to besterilizable, administrable by intravenous injection with minimal painand to exhibit a therapeutic index of greater than 5. In one embodiment,the (7) sulfobutyl ether β-cyclodextrin comprises less than 100 ppm of aphosphate and has an absorption of less than 0.5 AU due to adrug-degrading enzyme, as determined by UV/v is spectrophotometry at awave length of 245 nm to 270 nm for an aqueous solution containing 300mg of the dextrin per ml of solution in a cell having a 1 cm pathlength. In an embodiment, the formulation may also be storable in aplastic container.

The anaesthetic composition of the present invention may in oneembodiment comprise a buffer such as a phosphate or tris or citratephosphate buffer to maintain the pH from about 5.5 to about pH8. Thisincludes pH values of 5.5, 6, 6.5, 7, 7.5 and 8. Alternatively, thecomposition does not comprise a buffer and the pH being from about pH3to about pH 9.5 such as pH3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8,8.5, 9 or 9.5.

In a further aspect, the formulations of the present invention alsoinclude one or more agents such as excipients and/or preservatives,microbial retardants. Other agents may also be included to reducetoxicity. Agents include, for example, EDTA, benzyl alcohol,bisulphites, monoglyceryl ester of lauric acid (Monolaurin), capric acidand/or its soluble alkaline salts or its monoglyceryl ester(Monocaprin), edetate, and capric acid and/or its soluble alkaline saltsor its monoglyceryl ester (Monocaprin) and edentate. The formulation mayalso contain one or more co-polymers to assist in solubility orstability of the anaesthetic agent. Examples include hydroxy propylmethyl cellulose (HPMC), polyvinyl pyrollidone (PVP) and/orcarboxymethyl cellulose (CMC).

Conveniently, the neuroactive steroid anaesthetic is provided at aconcentration of from about 0.5 to 100 mg/ml in a saline suspensioncomprising the cyclodextrin. Such a concentration includes 0.5, 0.6,0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34,35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70,71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and 100 mg/ml of drug. Asindicated above, the composition is generally formulated so that themolar ratio of neuroactive steroid to cyclodextrin is from about 1:1 toabout 1:6, particularly from about 1:1 to 1:4, even more particularlyfrom about 1:1 to 1:3 and most particularly about 1:2.

Reference to any particular neuroactive steroid or their salts includesa racemic mixture of enantiomers of each anaesthetic as well as a singleenantiomer of the agent.

In a particular embodiment, the neuroactive steroid is alphaxalone,alphadolone and/or alphadolone acetate. In one embodiment, alphaxaloneis in the formulation at a concentration of from 1 to 100 mg/ml such as10 mg/ml. In another embodiment, alphadolone or alphadolone acetate ispresent at 0.5 to 50 mg/ml such as 3 mg/ml.

The formulations herein are for in vivo delivery meaning that theneuroactive steroid anaesthetic is delivered by intravenous,sub-cutaneous, intraperitoneal, intrathecal, intramuscular,intravitreal, transdermal, suppository (rectal), pessary (vaginal),inhalation, intranasal and the like. Most effectively, the formulationis an intravenous (iv) formulation.

Accordingly, another aspect of the present invention provides aninjectable formulation of a neuroactive steroid anaesthetic selected tobe sterilizable, administrable by intravenous injection with minimalpain, exhibiting a therapeutic index of greater than 5 and storable in aplastic container formulated with cyclodextrin, such as (7) sulfobutylether β-cyclodextrin or an alkyl ether derivative.

The neuroactive steroid anaesthetic may be used alone or in combinationwith another anaesthetic or sedative or other active agent. In oneembodiment, alphaxalone is used with alphadolone or its salt,alphadolone acetate. Hence, reference to “alphadolone” includesalphadolone acetate. The composition may comprise, therefore alphaxaloneor alphadolone alone or a combination of alphaxalone and alphadolone orany of their derivatives, salts or pro-drug forms.

Hence, in a particular embodiment, the present invention furtherprovides a composition comprising alphaxalone or a pharmacologicallyacceptable derivative, salt or pro-drug thereof and/or alphadolone or apharmacologically acceptable derivative, salt or pro-drug thereofformulated with a sulfoalkyl ether dextrin, such as (7) sulfobutyl etherβ-cyclodextrin wherein the molar ratio of alphaxalone and/or alphadoloneto dextrin is from about 1:1 to about 1:6. Reference can conveniently bemade to Remington's Pharmaceutical Sciences, Mack Publishing Company,Eaton, USA, 1990 and Rowe's Handbook of Pharmaceutical Excipients, 2009for formulation methods and reagents.

The present invention contemplates inducing or maintaining by infusionor intermittent bolus administration, anaesthesia in a human subject,the method comprising administering an anaesthetic-effective amount of aneuroactive steroid anaesthetic formulated with a cyclodextrin, such assulfoalkyl ether dextrin, for a time and under conditions to induceanaesthesia.

More particularly, the present invention provides a method of inducingor maintaining by infusion or intermittent bolus administration,anaesthesia in a human subject, the method comprising administering ananaesthetic-effective amount of a neuroactive steroid anaestheticselected from alphaxalone, alphadolone, acebrochol, allppregnanolone,eltanolone (pregnanolone), ganaxolone, hydroxydi one, minaxolone,Org20599, Org21465 and tetrahydrodeoxycorticosterone and apharmacologically acceptable derivative, salt or pro-drug form thereofformulated with a cyclodextrin, such as (7) sulfobutyl etherβ-cyclodextrin, for a time and under conditions sufficient to induceanaesthesia, wherein the anaesthetic formulation is sterilizable,administrateable by intravenous injection with minimal pain and exhibitsa therapeutic index of greater than 5. Additionally, the formulation caninitiate rapid anaesthesia with similar or more rapid wakening timecompared with propofol or Althesin (Registered Trademark). Theformulation may also be storable in a plastic container.

The present invention extends to inducing or maintaining by infusion orintermittent bolus administration, sedation. Hence, another aspect ofthe present invention provides a method of inducing or maintaining byinfusion or intermittent bolus administration, sedation in a subject,the method comprising administering a sedation-effective amount of aneuroactive steroid anaesthetic formulated with a cyclodextrin such, assulfoalkyl ether dextrin, for example, (7) sulfobutyl etherβ-cyclodextrin, for a time and under conditions sufficient to inducesedation.

Reference to “(7) sulfobutyl ether β-cyclodextrin” includes methylated,hydroxyalkylated, branched, alkylated, acylated and anionic derivativesthereof such as a sulfobutyl ether-alkyl ether β-cyclodextrin. Otherderives include β-cyclodextrin sulfobutyl ethers, ethyl ethers,β-cyclodextrin sulfobutyl ethers (flat), γ-cyclodextrin sulfobutylethers and α-cyclodextrin sulfobutyl ethers and their salts (e.g. sodiumsalts).

As indicated above, a particular subject is a human subject.

The anaesthetic formulation may be packaged for sale with instructionsfor use, The use includes a patient management protocol comprisingadministering to the patient an effective amount of neuroactive steroidanaesthetic such as selected from alphaxalone, alphadolone andpharmacologically acceptable derivatives, salts and pro-drug formsthereof formulated with a cyclodextrin such as a sulfoalkyl etherdextrin, for example, (7) sulfobutyl ether β-cyclodextrin, for a timeand under conditions sufficient to induce anaesthesia.

The present invention further contemplates the use of a neuroactivesteroid anaesthetic and a cyclodextrin, such as a sulfoalkyl etherdextrin, for example, (7) sulfobutyl ether β-cyclodextrin, in themanufacture of a medicament to induce anaesthesia in a subject such as ahuman subject. In a particular embodiment, the neuroactive steroidanaesthetic is selected from alphaxalone, alphadolone andpharmacologically acceptable derivatives, salts and pro-drug formsthereof. In another embodiment, the anaesthetic is selected fromacebrochol, allopregnanolone, eltanolone (pregnanolone), ganaxolone,hydroxydione, minaxolone, Org20599, Org21465 andtetrahydrodeoxycorticosterone and a pharmacologically acceptablederivative, salt or pro-drug form thereof.

In terms of an anaesthetic-effective amount, this is generally around0.25 mg/kg to about 100 mg/kg body weight. A sedative-effective amountis provided in similar or lower amounts and includes from about 0.05mg/kg to about 10 mg/kg body weight.

The present invention further provides a kit. The kit may be in any formincluding a syringe or modified syringe. A kit may comprise alphaxaloneand/or alphadolone or other neuroactive steroid anaesthetic or theirderivatives, salts or pro-drug forms in one or more compartments and asulfoalkyl ether dextrin in a further compartment as well as excipientsin subsequent compartments. The contents of the compartments may beadmixed prior to use.

In a particular embodiment, the present invention provides a formulationcomprising alphaxalone and/or alphadolone and/or pharmacologicallyacceptable derivatives, salts or pro-drug forms thereof complexed withthe sulfobutyl ether cyclodextrin, for use in inducing or maintaining byinfusion or intermittent bolus administration, anaesthesia or sedationin human subject.

The anaesthetic forms may be labeled such as deuterated or tritiatedforms or by other labels to facilitate monitoring and tracking of theanaesthetics in the body. Kits and apparatus are provided, therefore, tomonitor labeled neuroactive steroid anaesthetics.

Whilst the present invention is particularly directed to anaestheticformulations for use in humans, the formulations may also be used inanimals such as for clinical trials or veterinary use. Non-human animalscontemplated herein include rats, mice, guinea pigs, hamsters, sheep,pigs, dogs, cats, horses, cows, goats, camels and non-human primates.

Hence, the present invention provides an anaesthetic or sedativecomposition comprising a neuroactive steroid anaesthetic and acyclodextrin or modified form thereof wherein the composition has thefollowing properties:

-   (i) the neuroactive steroid and cyclodextrin are formulated in a    molar ratio of from about 1:1 to about 1:6;-   (ii) the neuroactive steroid is selected from alphaxalone,    alphadolone, acebrochol, allopregnanolone, eltanolone    (pregnanolone), ganaxolone, hydroxydionc, minaxolone, Org20599,    Org21465 and tetrahydrodeoxycorticosterone and a pharmacologically    acceptable derivative, salt or pro-drug form thereof formulated;-   (iii) the cyclodextrin is selected from an α-, β-, and    γ-cyclodextrin or a modified form thereof;-   (iv) a buffer is optionally present and when present the pH of the    formulation is from about pH5.5 to about pH8.0 and in the absence of    buffer, the pH is from about pH3 to about pH9.5;-   (v) the formulation is sterilizable;-   (vi) intravenous injection of the formulation induces less pain than    from a propofol formulation;-   (vii) the therapeutic index of the formulation is greater than 5;-   (viii) the formulation can be stored in a plastic container; and-   (ix) the formulation can initiate rapid induction of anaesthesia to    surgical levels with similar or more rapid wakening time compared to    propofol.

In a particular embodiment, an anaesthetic or sedative formulation isprovided comprising a sulfoalkyl ether or sulfoalkyl ether-alkyl etherdextrin, a neuroactive steroid anaesthetic such as alphaxalone oralphadolone and one or more co-polymers such as HPMC, PVP and/or CMC.

In a particular embodiment, the neuroactive steroid anaesthetic isformulated with a sulfoalkyl ether dextrin such as (7) sulfobutyl etherβ-cyclodextrin.

The present invention further contemplates a method for formulating ananaesthetic or sedative composition, the method generating a host/guestcomposition comprising a cyclodextrin and a neuroactive steroid. In anembodiment, the cyclodextrin is a sulfoalkyl ether or sulfoalkylether-alkyl ether dextrin such as (7) sulfobutyl either β-cyclodextrinor sulfobutyl ether-alkyl ether β-cyclodextrin. Other cyclodextrinsinclude β-cyclodextrin sulfobutyl ether-ethyl ether, β-cyclodextrinsulfobutyl ether (flat), γ-cyclodextrin sulfobutyl ether, α-cyclodextrinsulfobutyl ether and their sodium salts.

The present invention is further described by the following non-limitingExamples. When a neuroactive steroid anaesthetic is formulated with acyclodextrin, it is referred to as “neuroactive steroidanaesthetic_(CD)”. An example is Phaxan_(CD), which comprisesalphaxalone formulated with a cyclodextrin which in this case is (7)sulfobutyl ether β-cyclodextrin. Other examples includepregnanolone_(CD) and alphadolone_(CD)

Example 1 Anaesthetic Effects of Alphaxalone in 30% w/v (7) SulfobutylEther Acyclodextrin

Alphaxalone was formulated as 6 ml clear colorless liquid containing:

-   -   Alphaxalone 60 mg (10 mg/ml);    -   (7) sulfobutyl ether β-cyclodextrin 1800 mg;    -   Saline (0.9% w/v) 6 ml.

This is a molar complexation ratio of alphaxalone to (7) sulfobutylether β-cyclodextrin of 1:4.6: Male Wistar rats (weight [wt] 270-315 g)with indwelling jugular intravenous catheters were put in a Perspexrestrainer and given the injections with the attached observations uponrelease from the restrainer shown in Table 1.

TABLE 1 Effects of alphaxalone formulation on Wistar rats

The rats given 25 and 100 mg/kg body weight had recovered by 60 minutes;they did not die or suffer any adverse effects at these doses. In theseexperiments, it can be seen that intravenous injection of alphaxalone 10mg/ml dissolved in (7) sulfobutyl ether β-cyclodextrin caused loss ofconsciousness at doses above 10 mg/kg and there was a dose relatedanaesthetic effect with a wide safety margin; rats that received 25 and100 mg/kg body weight (two times and ten times the anaesthetic dose) didnot die indicating a wide safety margin for the preparation. This isclearly different from a formulation of alphaxalone in hydroxypropylβ-cyclodextrin. Such a preparation (AlfaxanCD-RTU) made by Jurox Pty,Newcastle NSW Australia has a published LD₅₀, the dose of alphaxalonethat causes death in 50% of rats when given intravenously, of 19 mg/kgbody weight, a figure very significantly below that shown here foralphaxalone formulated in sulfobutyl ether β-cyclodextrin [AlfaxanCD-RTU Material safety Data Sheet; Jurox Pty, Newcastle NSW Australia].

Example 2 Pharmacokinetics in the Rat

Two groups of ten rats with implanted internal jugular intravenous andcarotid intraarterial catheters receive bolus intravenous injections viathe jugular vein of 10 mg/kg body weight of (7) sulfobutyl etherβ-cyclodextrin formulation of alphaxalone (n=10 rats) or a mixture ofalphaxalone and alphadolone in CremophorEL (a polyethoxylated Casteroil), 1.1 ml/kg (n=10 rats). Blood taken from the carotid artery or tailat a number of time intervals after this injection is analyzed foralphaxalone blood levels. These are fitted to a three compartmentpharmacokinetic model and mean±sem for key parameters are calculated forboth preparations of steroid anaesthetic.

It is expected that there will be no significant difference between thePK parameters calculated for the (7) sulfobutyl ether β-cyclodextrinformulation and the Althcsin (Registered Trademark) formulation. Thiswould indicate that the new formulation is expected to behave in asimilar fashion to the way Althesin (Registered Trademark) has behavedin the past, particularly with respect to doses needed for anaesthesiaand sedation and also the speed of recovery. A sample table of bloodlevels that can be expected from these experiments appears in Table 2.

TABLE 2 Variable Units Duration of Anaesthesia Min 35.0 [9.0] AUC Min *mg/L 58.6 [11.7] t½(elim) Min 38.2 [5.6] Cl_(T) mL/min/kg 38.0 [8.2]V_(c) L/kg 0.5 [0.3] V_(dss) L/kg 1.8 [0.6]

Example 3 Anaesthetic Effects of Alphaxalone in (7) Sulfobutyl Etherβ-Cyclodextrin Compared with Alphaxalone as Afthesin (RegisteredTrademark) and Propofol

Male Wistar rats (wt 150-220 g weight) were implanted with indwellinginternal jugular vein intravenous catheters under halothane anaesthesia.Twenty four hours later each rat received an intravenous injection froma range of doses of either: propofol (10 mg/ml in 10% w/v Intralipidemulsion; Diprivan [Registered Trademark]); Althesin [RegisteredTrademark) (alphaxalone 9 mg/ml plus alphadolone acetate 3 mg/ml in 20%w/v CremophorEL); or Phaxan_(CD) (alphaxalone 10 mg/ml in a 1:2 molarcomplexation ratio with Captisol (Registered Trademark)-(7) sulfobutylether β-cyclodextrin). The following were assessed at regular timeintervals after the intravenous injection:

-   1. righting reflex: scored as: 1 normal; 2 slow; 3 some attempt; 4    none—this was a measure of onset and duration of unconsciousness;-   2 tail pinch response: scored as: 1 normal; 2 weak; 3 just present;    4 none—this was a measure of onset and duration of surgical    anaesthesia; and-   3. time to when the rat was able to walk on the rotarod (a rotating    cylinder) measured in seconds: the maximum normal run time is 120 s    in non sedated rats—attaining this value was a measure of time taken    to attain full recovery from the sedating effects of the anaesthetic    injections.

Results from groups of ten rats treated with the same anaesthetic anddose were combined for statistical purposes. Rats that attained a scoreof 4 for loss of righting reflex were deemed to have lost consciousnessand those that scored a 4 for loss of tail pinch response were deemed tobe surgically anaesthetized. The number of rats in each group of 10similarly, treated animals that scored 4 were subjected to probitregression analysis using SPSS Statistics 18 to produce graphs of probitvalue v log dose (probit plot) and also to calculate the estimated dosethat caused anaesthesia in 50 and 95% of subjects (A1)₅₀ and AD₉₅,respectively) for unconsciousness (righting reflex measurements) andsurgical anaesthesia (tail pinch responses). The rotarod walking timeswere also plotted for each dose and treatment. This was used as ameasurement of complete recovery. The results are shown in FIGS. 1 athrough 1 f, rotarod performance for each anaesthetic, n=10 rats perdose.

Table 3 below summarises the results of this series of experiments. Itcan be seen that Phaxan_(CD) is equipotent with Althesin (RegisteredTrademark) in causing unconsciousness and surgical anaesthesia and bothare more potent than propofol in this respect. Recovery fromunconsciousness caused by Phaxan_(CD) is just as fast as with propofol.However, recovery from Phaxan_(CD) is slightly slower than propofol butfaster than Althesin (Registered Trademark) if the depth of anaesthesiais taken to a surgical level. Control experiments revealed that thevehicles given alone intravenously, 20% CremophorEL, 10% Intralipid and13% Captisol had no sedating or anaesthetic effects.

TABLE 3 Althesin (Registered Trademark) Phaxan_(CD) propofol ANOVA withTukey post hoc minimum dose causing all 10 rats to lose righting reflexmg/kg 5 5

ED₅₀ dose for loss of righting reflex mg/kg 2.95 2.79

ED₉₅ dose for loss of righting reflex mg/kg 4.39 4.26

minimum dose causing all 10 rats to lose tall pinch response mg/kg 15 1515 ED₅₀ dose for loss of tail pinch response reflex mg/kg 6.46 6.56

ED₉₅ dose for loss of tail pinch response mg/kg 14.09 8.56

duration of loss of righting reflex at dose causing all 10 rats 3.6 1.92.5 not significant ANOVA p = 0.0527 to lose righting reflex (minutes)mean = SD = 2.18 0.84 1.15 duration of loss of tail pinch response atdose causing all 10 rats 13.45 4.65

Althesin vs Phaxan_(CD) *** P < 0.001; to lose tail pinch response(minutes) mean = Althesin vs propofol *** P < 0.001; SD = 3.9 2.55 1.28Phaxan_(CD) vs propofol ns P > 0.05 time (minutes) to overall (complete)recovery of rotarod performance 19.9 17

Althesin vs Phaxan_(CD) ns P > 0.05; after minimum anaesthetic dose(lost RR) mean = Althesin vs propofol * P < 0.05; SD = 3.93 2.16 1.89Phaxan_(CD) vs propofol ns P > 0.05 time (minutes) to overall (complete)recovery of rotarod performance 39 32.5 23.1 Althesin vs Phaxan_(CD) ***P < 0.001; after minimum surgical anaesthetic dose (lost tail pinch)mean = Althesin vs propofol *** P < 0.001; SD = 3.16 3.54 3.25Phaxan_(CD) vs propofol *** P < 0.001

indicates data missing or illegible when filed

It can be concluded from this set of experiments that:

-   -   Phaxan_(CD) is an effective intravenous anaesthetic causing fast        onset of general anaesthesia after intravenous injection.    -   It is equipotent with Althesin and twice as potent as propofol.

Example 4 Lethal Dose Finding for Alphaxalone Anaesthetic Preparations

This series of experiments was undertaken to determine the LD₅₀ and LD₉₅doses for alphaxalone formulated in CremophorEL [Althesin (RegisteredTrademark)] and (7) sulfobutyl ether β-cyclodextrin (Phaxan_(CD)); i.e.,the doses of alphaxalone in Captisol (Registered Trademark) that caused50% and 95% of subjects to die. Male Wistar rats (wt 150-220 g weight)were implanted with indwelling internal jugular vein intravenouscatheters under halothane anaesthesia. Twenty four hours later each ratreceived an intravenous injection from a range of doses of either:Althesin (Registered Trademark) (alphaxalone 9 mg/rn1 plus alphadoloneacetate 3 mg/ml in 20% CremophorEL); or Phaxan_(CD) (alphaxalone 10mg/ml in a 1:2 molar complexation ratio \ with Captisol (RegisteredTrademark)-(7)sulfobutyl ether β-cyclodextrin). The number of rats thatdied was recorded for each group of 10 rats given the same dose of drug.Results from groups of ten rats treated with the same anaesthetic anddose Were combined for statistical purposes. The graph of the raw datais shown in FIG. 2 [% rats died in each dosage group v dose].

At doses of alphaxalone between 50 and 60 mg/kg all the rats in theAlthesin (Registered Trademark) groups died whereas none died in thePhaxan_(CD) groups that received the same doses of alphaxalone. Thelethality values for Phaxan_(CD) showed a ceiling at 20%; no more than20% rats died even if the dose of alphaxalone administered asPhaxan_(CD) were increased. The percentages of rats that died in all thedifferent dosage treatment groups were subjected to a probit regressionanalysis using SPSS Statistics 18 and the probit values were plotted ona graph against the log dose of anaesthetic; this is called a probitplot. This is shown in FIG. 3.

The probit plot for Althesin (Registered Trademark) was used tocalculate the dose of alphaxalone in this formulation that caused deathin 50% and 95% rats; the LD₅₀ and LD₉₅ respectively). These values were43.6 mg/kg [LD₅₀] and 51.5 mg/kg [LD₉₅]. As the dose of alphaxalone wasincreased the number of rats that died increased in proportion when thealphaxalone was given as Althesin (Registered Trademark). By contrastthere was a ceiling effect of the lethality of the alphaxalone in (7)sulfobutyl ether β-cyclodextrin (Phaxan_(CD)) formulation. Thealphaxalone was much less toxic as assessed by lethality compared withalphaxalone formulated with CremophorEL (Althesin [RegisteredTrademark]). A dose of 52 mg/kg alphaxalone as Althesin (RegisteredTrademark) caused all 10 rats in that group to die but 64 mg/kgalphaxalone caused no deaths in the 10 rats which received that dose ofalphaxalone formulated with (7) sulfobutyl ether β-cyclodextrin(Phaxan_(CD)). Furthermore, unlike the probit plot for Althesin(Registered Trademark), which showed a direct proportional relationshipof increasing lethality with increasing dose, alphaxalone formulated in(7) sulfobutyl ether β-cyclodextrin (Phaxan_(CD)) showed a ceilingeffect for lethality; when the dose of alphaxalone in this preparationwas increased to 71, 78 and then 84 mg/kg only 20% of rats died in eachgroup. Thus, it was not possible to find the dose of alphaxalone in thisformulation that caused death in 50% and 95% rats (the LD₅₀ and LD₉₅,respectively). In any event, both of these values arc greater than 84mg/kg which is more than double the equivalent values for Althesin(Registered Trademark) and four times the value of the LD₅₀ foralphaxalone formulated in hydroxypropyl β-cyclodextrin manufactured byJurox [Alfaxan CD-RTU Material Safety Data Sheet. Jurox Pty, NewcastleNSW Australia].

These results make the therapeutic index (ratio of dose that causesdeath in 50% subjects (LD₅₀) divided by the dose that causes anaesthesiain 50% subjects (the AD₅₀) to be 14.8 for Althesin (RegisteredTrademark) and >30.2 for alphaxalone formulated in (7) sulfobutyl etherβ-cyclodextrin (Captisol [Registered Trademark] Phaxan_(CD)). Thisdifference is not due to differences in toxicity of the excipients.Table 4 below shows the results of experiments in 10 rats withindwelling jugular intravenous catheters. Five rats were given a 20%solution of Cremophor EL intravenously and another five rats were givena solution of (7) sulfobutyl ether β-cyclodextrin, both beingadministered at a dose and volume equal to that administered in theexperiments above at the highest dose of alphaxalone. Neither excipientcaused death in any rat indicating that the difference in thesafety/lethality of the two formulations of alphaxalone was not due todose related toxicity of the excipients.

TABLE 4 n/10 died vehicle dose = ml/kg 0 13% Captisol 9.0 0 20%Cremophor EL 4.6

Example 5 Demonstration of the Limitation of Alphaxalone Toxicity byCaptisol [Registered Trademark] (Sulfobutyl Ether β-Cyclodextrin)

Since the potency in causing anaesthesia is the same for a bolus dose ofalphaxalone whether given in 20% CremophorEL (Althesin [RegisteredTrademark]) or in (7) sulfobutyl ether β-cyclodextrin (Phaxan_(CD)),then the ceiling effect for toxicity must be related to the (7)sulfobutyl ether β-cyclodextrin when higher doses of alphaxalone in the(7) sulfobutyl ether β-cyclodextrin formulation are administered. Such aproperty has not been described for intravenous anaesthetics before.Furthermore, this property has not been described before for alphaxaloneformulated in other cyclodextrins.

In order to test whether the low toxicity of Phaxan_(CD) was due to theCaptisol excipient, twenty rats with indwelling jugular intravenouscatheters were divided into two groups of 10 rats each. They were allgiven intravenous injections of alphaxalone formulated in 20% Cremophorat a dose that had, in previous experiments reported in example 4,caused all rats to die (Althesin [Registered Trademark]; alphaxalonedose 52.5 mg/kg iv—this equals 16 times the AD₉₅ for Althesin(Registered Trademark) at which it is expected a very high proportion orall rats will die). Sixty seconds before the Althesin (RegisteredTrademark) injection a premedication injection was given:

-   -   group 1 (10 rats) received 5.3 mls/kg 0.9% sodium chloride        solution 60 seconds before 52.5 mg/kg alphaxalone as Althesin        (Registered Trademark);    -   group 2 (10 rats) received 5.3 mls/kg 13% solution of (7)        sulfobutyl ether β-cyclodextrin in 0.9% sodium chloride solution        60 seconds before 52.5 mg/kg alphaxalone as Althesin (Registered        Trademark).

The number of rats that died in each group was recorded shown in Table5. All 20 rats were anaesthetized by the injection of 52.5 mg/kgalphaxalone as Althesin (Registered Trademark). However, the presence of(7) sulfobutyl ether β-cyclodextrin caused a statistically andclinically significant reduction in the mortality caused by thealphaxalone.

TABLE 5 ALL RATS THAT SURVIVED WERE ANAESTHETISED >1 HOUR premed given60 s before Althesin @ 16 × AD95 premed volume = 5.25 mls/kg n died ndid not die SALINE PREMED 8 2 SBECD7 PREMED 2 8 Study Of The Effect ofCaptisol on the Death Rate of Althesin Fisher's Exact Test The two-sidedP value is 0.0230, considered significant. The row/column association isstatistically significant.

This is a much unexpected result.

Example 6 The Effect on Sleep Times of Repeated Dosing with Phaxan_(CD)

The mechanism responsible for the (7) sulfobutyl ether β-cyclodextrin incausing the ceiling effect on alphaxalone toxicity is unknown. It isknown that alphaxalone is very poorly soluble in water and thus the vastmajority of alphaxalone molecules are complexed with the cyclodextrinmolecules in the ratio of 1:2 (the complexation ratio). It is known thatsome of the alphaxalone will dissociate from the cyclodextrin complexwhen Phaxan_(CD) is injected intravenously. The question posed by theunique property of the alphaxalone sulfobutyl ether cyclodextrin complexexhibiting a ceiling effect for toxicity is whether this is caused bylimiting the amount of alphaxalone released from the complex or whetherthere occurs a “mopping up” of alphaxalone molecules that mightotherwise penetrate the brain to cause toxicity, by excess uncomplexedcyclodextrin molecules freed up by alphaxalone metabolism by the liver.The effect of the latter would be predicted to cause a progressivedecrease in the level of free alphaxalone as the concentration ofuncomplexed sulfobutyl ether cyclodextrin increased as a result of:

-   -   liver metabolism of the alphaxalone;    -   more doses of Phaxan_(CD) being administered thereby making more        uncomplexed cyclodextrin available.

If this were the case one would predict tolerance to repeated doses ofalphaxalone formulated in (7) sulfobutyl ether β-cyclodextrin i.e.,repeated injections of Phaxan_(CD) would cause progressively lesssedation and anaesthetic effect.

In order to test this five rats with indwelling jugular intravenouscatheters were given repeated injections of the minimum dose ofalphaxalone in (7) sulfobutyl ether β-cyclodextrin (5 mg/kg Phaxan_(CD))that had caused 10/10 rats to be anaesthetized as judged by completeloss of righting reflex. The time was measured for each rat to beginrecovery of righting reflex (progress from a score of 4 to a score of 3in the righting reflex as described in example 2 above) and then anotherdose of 5 mg/kg Phaxan_(CD) was given. The time to the beginning ofrecovery of the righting reflex after the second dose of anaesthetic wasmeasured and then another dose of 5 mg/kg Phaxan_(CD) was administerediv and the process was repeated eight more times. The progressiverecovery times for the first to the tenth doses are shown in thehistogram (FIG. 4) and table 6 below as means (sem) for those five rats.It can be seen that there was a significant progressive increase inrecovery times after each of the first four doses. Further doses 5-10caused no further significant increase and more importantly, nodecrease, in sleeping time. These results indicate that the alphaxalonetoxicity ceiling effect caused by the (7)sulfobutyl ether β-cyclodextrinis probably due to the controlled release of the alphaxalone from thecomplex at a rate sufficient to cause anaesthesia but no greater thanthat, no matter how much of the complex is given. This is a uniquebalance between the chemical relationship of the alphaxalone and the (7)sulfobutyl ether β-cyclodextrin, the low solubility of the alphaxalonein water environments, including biological fluids, the amount ofalphaxalone needed to penetrate the brain to cause anaesthesia and thepharmacokinetics of alphaxalone. The results are shown in FIG. 4 andTable 6. None of this was expected nor could have been predicted fromprior art.

TABLE 6 sleep time (mins) dose number mean sem first 0.8 0.14 second 2.50.35 third 2.9 0.41 fourth 3.2 0.45 fifth 3.7 0.38 sixth 4.1 0.21seventh 4.1 0.21 eighth 4.2 0.14 ninth 4.3 0.34 tenth 4.2 0.14

One way ANOVA [Tukey Kramer post hoc] applied to the data of sleep timesafter ×10 repeated dosing of 5 rats with Phaxan_(CD) 5 mg/kg revealedthat there was a progressive statistically significant increase insleeping time from the first to the second, second to the third andthird to the fourth but no increase in sleeping times thereafter.Furthermore it is important to note that there was not a progressivedecrease in sleeping times that would be predicted if the mechanism forlow toxicity and the ceiling effect of Phaxan_(CD) was due touncomplexed “free” sulfobutyl ether cyclodextrin [Captisol (RegisteredTrademark)] mopping up alphaxalone from the blood. If that were the casethen the amount of free uncomplexed Captisol would increase as moredoses were given and as alphaxalone was metabolized by the liver soleading to a progressive increase in free uncomplexed Captisol as therepeated exposure experiment progressed. If the alphaxalone were moppedup by this then one would expect less sleeping time with each successivedose. On the contrary the sleep time increased with each of the firstfour doses and then remained constant thereafter with each subsequentdose.

Example 7 Ceiling Toxicity

The following assumption is made:

A. that intravenous injection of Althesin (Registered Trademark) leadsto an instantaneous dispersal of alphaxalone in the plasma but, sinceanaesthesia is caused by drug injection in one circulation and alsoalphaxalone is cleared from the blood by the liver on first pass, thelevel achieved by the mixing in the plasma will only reach 30% of thetheoretical maximum assuming instantaneous mixing.

The following is considered:

-   1. alphaxalone is soluble in water to 0.03 mg/ml;-   2. alphaxalone is 35% protein bound in plasma;-   3. plasma volume is 31 ml/kg in rat (Davies and Morris,    Pharmaceutical Research, 10(7):1093-95, 1993);-   4. both Althesin (Registered Trademark) and Phaxan_(CD) have    alphaxalone concentrations of 10 mg/ml;-   5. for induction of anaesthesia Althesin (Registered Trademark) and    Phaxan_(CD) arc equipotent; a minimum of 4.3 mg/kg alphaxalone by    either preparation cause sleep in most (95%) rats;-   6. after an initial bolus injection a drug preparation will    equilibrate with the plasma volume during the first sleep cycle but    later the drug will disperse into the extracellular fluid [ECF]    which is =297 ml/kg (Davies and Morris, 1993 supra);-   7. Captisol is distributed to ECF and restricted to this space; and-   8. Alphaxalone is only released from the Captisol into an aqueous    environment if the level of free alphaxalone in the aqueous    environment is less than saturation i.e., <0.03 mg/ml [fact 1].

It is proposed herein that:

-   1. From A and 5 above, the plasma level of drug needed to cause    sleep dose administered as Althesin/plasma volume=4.3/31=0.14 mg/ml.-   II. Applying A, the plasma concentration is expected to be 30% of    this when the blood has circulated to mix the drug effectively=0.046    mg/ml.-   III. From this, the level of free unbound alphaxalone in the plasma    associated with anaesthesia induction after a single iv bolus    injection=65% of total (from fact 2)=0.045×0.65=0.03 mg/ml.-   IV. Proposition III above is exactly the known solubility of    alphaxalone in water.-   V. Combining points 5 and 8 with proposition IV, it is proposed    herein that the first induction dose of Phaxan_(CD) caused    anaesthesia by releasing all of the alphaxalone from the complex    just achieving the anaesthetic level and free alphaxalone saturation    level.-   VI. When the second dose of anaesthetic was administered in Example    9 the rat was starting to recover from the anaesthetic because some    free alphaxalone had been metabolized by the liver, some free    alphaxalone had been redistributed to the ECF and some of the    Captisol containing alphaxalone had also redistributed to the ECF.    Thus, the free alphaxalone level fell and alphaxalone left the brain    so causing awakening. Thus, a further dose was given. Unlike the    first dose, there was still alphaxalone in the blood so only some of    the alphaxalone was released from the complex to bring the free    alphaxalone level back to 0.03 mg/ml; the brain is reloaded and    sleep follows.-   VII. However, sleep follows for a longer time after the second dose    and the third and also the fourth until the ECF is loaded with 0.03    mg/ml alphaxalone and alphaxalone/Captisol complex [points 6 and 7].    After that further doses of Captisol merely top up the blood level    of free alphaxalone and maintain it until hepatic metabolism has    cleared that dose of alphaxalone.-   VIII. Once the level of free alphaxalone reaches 0.03 mg/ml, the    brain is anaesthetized. The brain will only absorb more alphaxalone    if the level of free alphaxalone increases. This is possible with    Althesin (Registered Trademark) and death ensues when 15 times the    anaesthetic dose of that drug is administered as a bolus leading to    a theoretical free alphaxalone level of 0.45 mg/ml. In contrast,    when that dose of alphaxalone is given as Phaxan_(CD), in a complex    with Captisol (Registered Trademark), the alphaxalone is not    released from the complex once the level of free alphaxalone reaches    0.03 mg/ml [point 1]. This explains the ceiling effect on lethality    with alphaxalone when formulated in 13% sulfobutyl-7-ether    β-cyclodextrin.-   IX. Since no further increase in sleep time occurs after the fifth    dose of 5 mg/kg Phaxan_(CD) and subsequent doses of the same    magnitude, then the clearance of alphaxalone must be in equilibrium    with the dose administration rate. The equilibrium clearance of    alphaxalone is therefore 5 mg/kg/4.2 min. Since the concentration in    plasma is approximately 0.04 mg/ml then the plasma clearance rate at    equilibrium=((5÷4.2)÷0.04)=30 mls/kg/min. This is within known    values of hepatic blood flow (Davies and Morris, 1993 supra). It is    well known that alphaxalone is primarily cleared from plasma by    first pass hepatic metabolism.-   X. The latter implies that this particular formulation of    alphaxalone in sulfobutyl ether β-cyclodextrin controls the level of    free unbound anaesthetic that penetrates the brain up to but not    above a level that causes anaesthesia; the Captisol cannot release    any more compound above the level at which plasma water is saturated    with alphaxalone and thus higher blood levels that would cause    toxicity are not achieved.

This property has not been described for intravenous anaesthetics orintravenous cyclodextrins before. It arises from a unique set ofcircumstances not described or previously discovered:

-   1. A unique host:guest interaction. The evidence for this is the    fact that the same guest [alphaxalone] formulated in another host    cyclodextrin (Alfaxan_(CD)-RTU; hydroxypropyl β-cyclodextrin—the    Jurox preparation) does not have a ceiling on toxicity with a quoted    LD₅₀ of 19 mg/kg iv in rats, a dose which is 75% less than the dose    of alphaxalone in the (7) sulfobutyl ether β-cyclodextrin which only    causes 20% lethality;-   2. The guest is a compound that causes anaesthesia at a free drug    level which is equal to its aqueous solubility; and-   3. The guest is a compound that has a high therapeutic index so that    the free drug level is well below the toxic level.

Example 8 Pregnanolone Formulation

The neuroactive steroid anaesthetic pregnanolone was mixed with 13% w/vsulfobutyl ether β-cyclodextrin (Captisol [Registered Trademark]) in0.9% saline to form pregnanolone_(CD). The pregnanolone dissolvedincompletely at a concentration of 10 mg/ml, and unlike alphaxalone, itonly went into solution after 4 hours of continuous stirring. Thesolution was opalescent. This observation indicates that all neuroactivesteroids do not interact with (7) sulfobutyl ether β-cyclodextrin in thesame way. Fifteen male Wistar rats (150-200 g weight) withsurgically-implanted internal jugular intravenous catheters were usedfor these experiments in which they received intravenouspregnanolone_(CD) injections: 2.5 mg/kg (n=5); 5 mg/kg (n=5); and 10mg/kg (n=5).

They were assessed for anaesthesia by the righting reflex which wasscored: 1 normal; 2 slow; 3 some attempt; 4 none. A score of 4 meansthat a state of unconsciousness (anaesthesia) has been achieved. FIG. 5below shows the results from this test for the rats in the three groupsthat received 2.5, 5 and 10 mg/kg pregnanolone. Results shown are meansof the readings from all 5 rats at each time point after intravenousinjection of pregnanolone.

The rats were also assessed for surgical anaesthesia using tail pinchresponses scored: 1 normal; 2 weak; 3 just present; 4 none. A score of 4indicates surgical anaesthesia has been achieved. FIG. 6 shows theresults from this test for the rats in the three groups that received2.5, 5 and 10 mg/kg pregnanolone_(CD). Results shown are means of thereadings from all 5 rats at each time point after intravenous injectionof pregnanolone_(CD).

Time to complete recovery from the sedating effects of thepregnanolone_(CD) was assessed with the rotarod run time—normalnon-sedated rats run on the accelerating rotating drum is 120 seconds;rats are fully recovered when they can walk on the rotarod treadmill for120 seconds. FIG. 7 below shows the results from this test for the ratsin the three groups that received 2.5, 5 and 10 mg/kg pregnanolone_(CD).Results shown are means of the readings from all 5 rats at each timepoint after intravenous injection of pregnanolone_(CD).

Conclusions

Pregnanolone_(CD) is an intravenous anaesthetic but of long duration. Itcauses anaesthesia induction immediately after intravenous injection.This effect is dose related and it is possible to cause sufficient CNSdepression to lead to surgical anaesthesia.

Example 9 Alphadolone Formulation

The neuroactive steroid anaesthetic alphadolone was mixed with 13% w/vsulfobutyl ether β-cyclodextrin (Captisol) in 0.9% w/v saline to formalphadolone_(CD)). The alphadolone dissolved completely at aconcentration of 10 mg/ml, but unlike alphaxalone, it only, went intosolution after 4 hours of continuous stirring. This observationindicates that all neuroactive steroids do not interact with (7)sulfobutyl ether β-cyclodextrin in the same way. Fifteen male Wistarrats (150-200 g weight) with surgically-implanted internal jugularintravenous catheters were used for these experiments in which theyreceived intravenous alphadolonecn injections: 10 mg/kg (n=5); 20 mg/kg(n=5); and 40 mg/kg (n=5).

They were assessed for anaesthesia by the righting reflex which wasscored: 1 normal; 2 slow; 3 some attempt; 4 none. A score of 4 meansthat a state of unconsciousness (anaesthesia) has been achieved. FIG. 8shows the results from this test for the rats in the three groups thatreceived 10, 20 and 40 mg/kg alphadolone_(CD). Results shown are meansof the readings from all five rats at each time point after intravenousinjection of alphadolone.

The rats were also assessed for surgical anaesthesia using tail pinchresponses scored: 1 normal; 2 weak; 3 just present; 4 none. A score of 4indicates surgical anaesthesia has been achieved. FIG. 9 shows theresults from this test for the rats in the three groups that received10, 20 and 40 mg/kg alphadolone_(CD). Results shown arc means of thereadings from all five rats at each time point after intravenousinjection of alphadolone_(CD).

Time to complete recovery from the sedating effects of thealphadolone_(CD) was assessed with the rotarod run time—normalnon-sedated rats run on the accelerating rotating drum is 120 seconds;rats are fully recovered when they can walk on the rotarod treadmill for120 seconds. FIG. 10 shows the results from this test for the rats inthe three groups that received 10, 20 and 40 mg/kg alphadolone_(CD).Results shown are means of the readings from all 5 rats at each timepoint after intravenous injection of alphadolone_(CD),

Conclusions

Alphadolone_(CD) is an intravenous anaesthetic of short duration. Itcauses anaesthesia induction immediately after intravenous injection.This effect is dose related and it is possible to cause sufficient CNSdepression to lead to surgical anaesthesia.

Example 10 Cardiovascular Effects of Phaxan_(CD) Compared with Althesinand Propofol

Fifteen male Wistar rats (150-200 g weight) with surgically-implantedinternal jugular intravenous catheters were used for these experimentsin which rats in three groups received intravenous injections ofequipotent AD₉₅ anaesthetic doses of either propofol (6.6 mg/kg;Diprivan 10 mg/ml propofol in 10% Intralipid emulsion), Althesin (3.28mg/kg alphaxalone; Althesin 9 mg/ml alphaxalone plus 3 mg/ml alphadolonedissolved in 20% CremophorEL), or Phaxan_(CD) (3.23 mg/kg alphaxalone;alphaxalone 10 mg/ml dissolved in Captisol [(7) sulfobutyl etherβ-cyclodextrin] 13%); n=5 rats per group. Systolic and diastolic bloodpressures were measured before and after these injections. Eachmeasurement was calculated as a percentage change from thepre-anaesthetic levels for that rat. FIGS. 11 and 12 show the percentagechanges against time for each of the cardiovascular parameters in eachtreatment group.

Conclusion

Both formulations of alphaxalone (Althesin/20% CremophorEL;Phaxan_(CD)/sulfobutyl ether β-cyclodextrin (Captisol [RegisteredTrademark])) caused less cardiovascular disturbance than anequianaesthetic dose of propofol and in one measure (diastolic bloodpressure) the sulfobutyl ether β-cyclodextrin formulation of alphaxalone(Phaxan_(CD)) caused less cardiovascular disturbance compared with theCremophorEL preparation (Althesin [Registered Trademark]).

Example 11 A Phase ½a Clinical Trial

In these experiments in human volunteers, propofol and (7) sulfobutylether β-cyclodextrin/alphaxalone formulation are compared in a doubleblind manner. Each volunteer is prepared in a fully equipped anaestheticroom. Dosing with either propofol or alphaxalone is determined by arandomization schedule to either propofol or alphaxalone. Oneanaesthetist designated to give the anaesthetic opens an envelope tofind which drug should be given to this patient. The dose of drug isdetermined from a calculation schedule (see below) relying on theresponse of the previous patient to the last dose of that drugused—anaesthesia achieved or not based on a measurement of 50 for thebispectral index of the electroencephalogram (BIS value). The patienthas an intravenous cannula in the right hand for drug administration andanother for blood withdrawal for samples for measurements of bloodlevels of drug. That arm and the anaesthetist administering theanaesthetic has no communication with the test subject or a secondanaesthetist who is in contact with the subject and who is responsiblefor general care of the subject as well as physiological monitoring. Thearm and the drug administering anaesthetist are separated by a curtainfrom the anaesthetist caring for the subject as well as the subject andanaesthetic nurse present. The first, drug injecting anaesthetist, onlycommunicates that the anaesthetic injection is about to start by ringinga bell and the caring anaesthetist only communicates with the drugadministering anaesthetist to say whether a BIS value of 50 or less wasachieved after that subject leaves the room at the end of theexperiment. Measurements and assessments made:

-   -   Subjects weight in kg. This is written on the case record before        passing to the administering anaesthetist.    -   The patient is asked by the caring anaesthetist to report pain        on injection and a positive or no report is noted.    -   Presence or absence of abnormal movements is noted by the caring        anaesthetist. 4    -   Time from the ringing of the bell indicating anaesthetic        injection to the subject dropping a water-loaded 20 ml syringe        held between finger and thumb in the outstretched left arm.    -   Time from the ringing of the bell indicating anaesthetic        injection to loss of verbal contact with the patient and time        for that contact to return.    -   Time from the ringing of the bell indicating anaesthetic        injection to the subject losing the eyelash reflex and the time        at which that reflex returned.    -   BIS value and whether a value of 50 or below is achieved and        when and for how long after the intravenous injection.    -   Blood pressure, systolic and diastolic, and pulse rate using non        invasive methods measured every 1 minute for 5 minutes, every        2.5 minutes for a further 10 minutes and every 5 minutes        thereafter.    -   Oxygen saturation of the blood measured with a pulse oximeter        probe placed on the ear lobe of the left ear. The subject        breathes air unless oxygen saturation levels fall below 93% at        which time oxygen is given by face mask and anaesthetic circuit.        Breathing is assisted if apnoea occurs and persists for longer        than 30 seconds. The occurrence of low oxygen saturations and        apnoea are noted.    -   Time to full recovery indicated by normal performance in a        digital substitution test    -   Blood taken for analysis of alphaxalone blood levels at 0.5,        1.0, 1.5, 2, 5 10, 15, 30 and 60 minutes after anaesthetic        injection.    -   Blood taken before the experiment, one hour after the experiment        and 24 hours and one week later for:        -   Full haematological analysis.        -   Hepatic function tests.        -   Renal function tests.

Dose Schedule

When the envelope is opened by the administering anaesthetist therandomized instruction will be to give propofol or alphaxalone. If thisis the first subject to receive the drug they are given: propofol 2mg/kg; alphaxalone 0.5 mg/kg.

-   -   The dosing for the next patient to receive that drug is        determined by the response of the first subject given that drug.        -   If the first subject did not achieve a BIS of 50 or less,            then for propofol the dose would be 3 mg/kg and for            alphaxalone 0.75 mg/kg.        -   If the first subject did achieve a BIS of 50 or less, then            for propofol the dose would be 1 mg/kg and for alphaxalone            0.25 mg/kg.    -   Thereafter the dosing is:        -   a decrease of dose of 25% if all subjects so far treated            with that drug achieved a BIS of 50 or,        -   an increase of dose of 25% if all subjects so far treated            with that drug had all not achieved a BIS of 50 or,        -   In the case that there have been some subjects treated with            this drug that have achieved BIS values of 50 or less and            others with BIS values that have not fallen to 50 or less            then either:            -   In the case of the last response being a BIS of 50 or                less, then the dose of drug for the next subject to                receive this drug will be mid way between the dose for                the last subject given that drug and the dose given to                the most recent previous subject given that drug and who                did not achieve a BIS of 50 or below.            -   In the case of the last response being a BIS greater                than 50, then the dose of drug for the next subject to                receive this drug will be mid way between the dose for                the last subject given that drug and the dose given to                the most recent previous subject given that drug who did                achieve a BIS of 50 or below.            -   The latter is repeated for each drug series until the                dose range variations have become small and six subjects                have achieved a BIS value of 50 or less having received                the same dose±10% of drug. These 6 doses achieving                anaesthetic levels of BIS are combined to calculate the                mean±sem induction dose.

The following results are expected:

-   -   Alphaxalone causes general anaesthesia with BIS values <50        achievable in one arm/brain circulation time.    -   The quality of induction is at least as good as with propofol        but with the added advantage of no pain on injection.    -   At the “induction dose”, propofol causes greater falls in blood        pressure, an increased incidence of apnoea and decreased oxygen        saturation than alphaxalone.    -   After administration of the “induction dose” the speed and        quality of recovery is faster for alphaxalone.    -   The pharmacokinetics of alphaxalone after intravenous        administration are the same as for the alphaxalone figures in        the literature after Althesin (Registered Trademark)        administration.

Those skilled in the art will appreciate that the invention describedherein is susceptible to variations and modifications other than thosespecifically described. It is to be understood that the inventionincludes all such variations and modifications. The invention alsoincludes all of the steps, features, compositions and compounds referredto, or indicated in this specification, individually or collectively,and any and all combinations of any two or more of said steps orfeatures.

BIBLIOGRAPHY

-   Atwood, Davies, MacNicol and Vogtie (Eds), Comprehensive    Supramolecular Chemistry Vol 4, Pergamon: Oxford UK, 1996-   Child et al., British Journal of Anaesthesia 43:2-13, 1971-   Davies and Morris, Pharmaceutical Research, 10(7):1093-95, 1993-   Fromming and Szejtlic (eds), Cyclodextrins in Pharmacy, Kluwer:    Dordrecht, The Netherlands, 1994-   Remington's Pharmaceutical Sciences, Mack Publishing Company, Eaton,    USA. 1990-   Rowe's Handbook of Pharmaceutical Excipients, 2009-   Thomason, Crit. Rev Ther Drug Carrier Syst 14:1, 1997-   Uekama et al., Chem. Rev. 98: 2045-2076, 1998

1. An anaesthetic or sedative delivery host/guest composition comprisinga cyclodextrin host or modified form thereof with a neuroactive steroidanaesthetic drug guest, the host/guest composition formulated to besterilizable, administrate by intravenous injection with minimal painand to exhibit a therapeutic index of greater than
 5. 2. The compositionof claim 1 wherein the neuroactive steroid anaesthetic is selected fromalphaxalone, alphadolone, acebrochol, allopregnanolone, eltanolone(pregnanolone), ganaxolone, hydroxydione, minaxolone, Org20599, Org21465and tetrahydrodeoxycorticosterone and a pharmacologically acceptablederivative, salt or prodrug form thereof.
 3. The composition of claim 1,wherein the molar ratio of neuroactive steroid anaesthetic tocyclodextrin is from about 1:1 to 1:6.
 4. The composition of claim 3,wherein the molar ratio of neuroactive steroid anaesthetic tocyclodextrin is from about 1:1 to about 1:4.
 5. The composition of claim4, wherein the molar ratio of neuroactive steroid anaesthetic tocyclodextrin is about 1:2.
 6. The composition of claim 1, furthercomprising one or more of an antimicrobial agent, a preservative, abuffer and/or a co-polymer.
 7. The composition of claim 6, wherein theco-polymer is selected from the group consisting of hydroxy propylmethyl cellulose, polyvinyl pyrollidone and carboxymethyl cellulose. 8.The composition of claim 6, wherein if a buffer is present, the pH isfrom about pH 5.5 to about pH
 8. 9. The composition of claim 1, whereinthe cyclodextrin is a β-cyclodextrin or a modified form thereof.
 10. Thecomposition of claim 9 wherein the modified form of β-cyclodextrin is asulfoalkyl ether cyclodextrin or a methylated, hydroxy alkylated,branched, alkylated, acylated or anionic derivative thereof.
 11. Thecomposition of claim 10 wherein the sulfoalkyl ether β-cyclodextrin is(7) sulfobutyl ether β-cyclodextrin.
 12. The composition of claim 10wherein an alkylated derivative is a sulfoalkyl elher-alkyl etherderivative.
 13. The composition of claim 1, wherein the cyclodextrin isselected from the group consisting of β-cyclodextrin sulfobutylether-ethyl ether, β-cyclodextrin sulfobutyl ether (flat),γ-cyclodextrin sulfobutyl ether, α-cyclodextrin sulfobutyl ether andtheir sodium salts.
 14. The composition of claim 1 wherein thecomposition initiates rapid induction of anaesthesia with similar ormore rapid awakening time relative to propofol.
 15. An anaesthetic orsedative composition comprising a neuroactive steroid selected from thegroup consisting of alphaxalone, alphadolone, acebrochol,allopregnanolone, eltanolone (pregnanolone), ganaxolone, hydroxydione,minaxolone, Org20599, Org21465 and tetrahydrodeoxycorticosterone, and apharmacologically acceptable derivative, salt or prodrug form thereofformulated with a sulfoalkyl ether dextrin or modified form thereof togenerate a sterilizable composition with a therapeutic index of greaterthan
 5. 16. The anaesthetic or sedative composition of claim 15 whereinthe neuroactive steroid anaesthetic is alphaxalone and/or alphadolone orpharmacologically acceptable derivatives including deuteratedderivatives, salts and prodrug forms thereof.
 17. The anaesthetic orsedative composition of claim 15, wherein the sulfoalkyl ether dextrinis (7) sulfobutyl ether β-cyclodextrin or an alkyl ether derivativethereof.
 18. The anaesthetic or sedative composition of claim 17 whereinthe dextrin is sulfobutyl ether-alkyl ether cyclodextrin.
 19. Theanaesthetic or sedation composition of claim 15, wherein thecyclodextrin is selected from the group consisting of β-cyclodextrinsulfobutyl ether-ethyl ether, β-cyclodextrin sulfobutyl ether (flat),γ-cyclodextrin sulfobutyl ether, α-cyclodextrin sulfobutyl ether andtheir sodium salts.
 20. A method of inducing or maintaining by infusionor intermittent bolus administration, anaesthesia or sedation in asubject, the method comprising administering an anaesthetic- orsedative-effective amount of a composition of claim
 1. 21. The method ofclaim 20 wherein the neuroactive steroid anaesthetic agent isalphaxalone, alphadolone and/or alphadolone acetate.
 22. The method ofclaim 21 wherein alphaxalone and/or alphadolone is/are used atanaesthetic concentration of 0.25 mg/kg to 100 mg/kg body weight. 23.The method of claim 21 wherein the alphaxalone is used at a sedatingconcentration of 0.05 mg/kg to 10 mg/kg body weight.
 24. The method ofclaim 20, wherein the subject is a human. 25.-30. (canceled)
 31. Amethod of inducing or maintaining by infusion or intermittent bolusadministration, sedation in a human subject, said method comprisingadministration to said subject a sedating-effective amount of aneuroactive steroid anaesthetic selected from the group consisting ofalphaxalone, alphadolone and pharmacologically acceptable derivatives,salts and pro-drug forms thereof formulated with a sulfoalkyl etherdextrin or modified form thereof.
 32. The method of claim 31 wherein thesulfoalkyl ether dextrin is (7) sulfobutyl ether β-cyclodextrin or analkyl ether derivative thereof.
 33. The method of claim 32 wherein thedextrin is a sulfobutyl ether-alkyl ether cyclodextrin.
 34. The methodof claim 31 wherein the sulfoalkyl ether dextrin is selected fromβ-cyclodextrin sulfobutyl ether-ethyl ether, β-cyclodextrin sulfobutylether (flat), γ-cyclodextrin sulfobutyl ether, α-cyclodextrin sulfobutylether and their sodium salts.
 35. The method of claim 31 wherein thesubject is a human.